Name

Nagi Bioscience

Legal name

Nagi Bioscience SA

Website

https://nagibio.ch

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Automated in vivo screening instruments

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Prepackaged Software (7372)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• Organism-on-chip technology
• Aging research platforms
• Contract research services
• Biological age measurement
• In vivo screening assays

Headquarters

HQ city

Saint-sulpice

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services (CRO): Full-service contract research offerings including aging and longevity studies, neurodegenerative studies, toxicity studies, compound efficacy studies, microbiome studies, and custom studies. Clients send compounds of interest and receive comprehensive reports with actionable insights.
2. SydLab™ One Discovery Pack: On-site research experience program where clients conduct experiments at Nagi Bioscience facilities in Switzerland. Includes guided hands-on training, real-time data visualization, and results review sessions.
3. Software Modules: Sale of SydLab™ Analyzer software modules including Toxicity Profiling, Lifespan and Healthspan, and Fluo-Based Assays modules for customers operating their own SydLab™ One platforms.
4. Consumables & Reagents: Sale of assay kits and reagents for C. elegans testing workflows.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Nagi Bioscience develops and commercializes the SydLab™ One automated Organism-on-Chip platform that uses the C. elegans model organism to deliver high-throughput in vivo measurement of lifespan, healthspan, and biological age in a single workflow. The company sells the SydLab™ One instrument, AI-powered SydLab™ Analyzer software modules, Nagi™ assay products (C-Age and B-Age), and consumables/reagents, alongside full-service contract research offerings spanning aging and longevity studies, neurodegenerative studies, toxicity testing, compound efficacy studies, and microbiome studies.

Product overview

Nagi Bioscience is a Swiss biotech company that has developed a portfolio of products centered around its SydLab™ One Platform — the first fully automated Organism-on-Chip solution for high-throughput aging and longevity research using C. elegans. The platform integrates proprietary AI-powered software modules (SydLab™ Analyzer) with specialized assay products including Nagi™ C-Age (lifespan and motility measurement) and Nagi™ B-Age (biological age and healthspan measurement in 10 days). These assay products can be run individually or combined within the SydLab™ One workflow for maximum insight. The company also offers comprehensive Contract Research Services spanning aging and longevity studies, neurodegenerative studies, toxicity studies, compound efficacy studies, and microbiome studies. A Discovery Pack program provides hands-on access to the platform at their Swiss facilities.

Differentiator

Problem solved

Functional benefit

Brands

• SydLab™ One: The first fully automated Organism-on-Chip platform for high-throughput, reproducible aging insights using C. elegans at client sites.
• Nagi™ B-Age
• Nagi™ C-Age
• Nagi™ B-Age for Gut Health
• SydLab™ Analyzer
• Nagi™ Assay Kits

Products and services

• SydLab™ One Platform The first fully automated Organism-on-Chip platform delivering reproducible, high-throughput aging insights to study human longevity and age-related diseases on C. elegans. Enables continuous, high-resolution phenotyping throughout the organism's lifespan under strictly controlled environmental conditions. Sold to organizations wanting to operate the platform at their own site.
• Nagi™ B-Age AI-powered in vivo biological age and healthspan measurement assay that delivers results in just 10 days. Dissects the mechanism of action among 5 vital traits to provide multidimensional insights into aging trajectories for healthy aging discovery and longevity innovation.
• Nagi™ C-Age High-throughput in vivo measurement of lifespan and motility providing multidimensional insights in a single assay, including mean and maximum lifespan, healthspan markers, and biological age. Used for healthy aging discoveries and longevity interventions.
• Nagi™ B-Age for Gut Health Specialized biological age measurement assay focused on gut health innovations and microbiome-related aging research, adapted from the B-Age assay for gut and microbiome studies.
• SydLab™ Analyzer Software Modules Comprehensive software suite including a user-friendly experiment launcher, AI-based high-content data extraction algorithm extracting 30+ features per time point per organism, real-time visualization, and customizable phenotypic fingerprinting analyses. Modules include Toxicity Profiling, Lifespan and Healthspan, and Fluo-Based Assays, sold to customers operating their own SydLab™ One platforms.
• SydLab™ One Discovery Pack Two-day on-site program offering researchers the opportunity to conduct their own experiments at Nagi Bioscience's Saint-Sulpice, Switzerland facilities. Includes guided hands-on experience with the SydLab™ One platform, training on data logging and parameter setup, and real-time visualization of experimental progress.
• Consumables & Reagents (Nagi™ Assay Kits) Assay kits and reagents for conducting C. elegans-based aging and longevity studies, supporting the SydLab™ One platform and Nagi™ assay products.
• Aging and Longevity Studies (Contract Research) High-throughput, fully automated contract research studies using C. elegans providing mean/maximum lifespan, healthspan (motility, growth, reproduction), biological age, and 5 vital traits measurements for pharmaceutical, biotech, nutraceutical, and academic clients.
• Neurodegenerative Studies (Contract Research) In vivo contract research studies for Alzheimer's, Parkinson's, Huntington's, and ALS using C. elegans models with fluorescence markers, motility readouts, and protein aggregation monitoring.
• Toxicity Studies (Contract Research) Developmental and Reproductive Toxicity (DART) testing and general toxicity profiling using automated in vivo C. elegans assays for compound safety assessment.
• Compound Efficacy Studies (Contract Research) High-throughput contract research screening services to evaluate compound efficacy for longevity, healthspan improvement, and therapeutic potential using C. elegans models.
• Microbiome Studies (Contract Research) Contract research studies focusing on microbiome-gut-brain axis interactions and their effects on aging using C. elegans models and the SydLab™ One platform.

Quantifiable outcome

• 10-day biological age measurement turnaround with Nagi™ B-Age assay
• +2 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Telomir PharmaceuticalscoreStrategic or Co-development PartnerPartnership in longevity and age-related disease research. Telomir uses Nagi Bioscience's automated C. elegans platform to gather critical scientific data for their therapeutic development programs.
• DTU Biosustain / Novo Nordisk FoundationcoreStrategic or Co-development PartnerAcademic collaboration on healthy aging innovations. DTU Biosustain researchers use Nagi's SydLab™ One platform to explore the potential of bacterial strains in health applications related to healthy aging.
• Bayer CropSciencecoreStrategic or Co-development PartnerCollaboration on developmental and reproductive toxicity (DART) testing using Nagi's C. elegans platform as an alternative to traditional animal testing.
• Immunic TherapeuticscoreStrategic or Co-development PartnerPartnership for efficacy screening in immune and neurodegenerative therapeutics development. Immunic uses Nagi's automated platform as alternative to mouse studies.
• Harvard T.H. Chan School of Public HealthcoreStrategic or Co-development PartnerAcademic collaboration using SydLab One platform for aging biology research, metabolism and diet studies in healthy aging research.
• National and Kapodistrian University of Athens (NKUA)coreStrategic or Co-development PartnerProf. Palikaras' laboratory uses SydLab One and Nagi B-Age platforms for research on aging mechanisms and neurodegeneration, including combined interventions against Alzheimer's Disease.
• ICMAB - Institut de Ciència de Materials de BarcelonaminorStrategic or Co-development PartnerCollaboration on microplastics ecotoxicology research using Nagi Bioscience's C. elegans testing technology.
• International Iberian Nanotechnology Laboratory (INL)minorStrategic or Co-development PartnerSafety toxicology testing of nanoparticles and their effects on neurodegeneration models using Nagi's automated platform.
• ElixIRA Pharma AGcoreStrategic or Co-development PartnerSwiss longevity biotech using Nagi's high-throughput C. elegans screening to evaluate synergistic effects of combination therapies on lifespan, motility, and biological age.
• European Research Institute for Biology of Ageing (ERIBA)coreStrategic or Co-development PartnerProf. Ellen Nollen's lab uses SydLab One platform for molecular neurobiology of aging research, generating high-throughput data with high resolution.
• YeastUpminorStrategic or Co-development PartnerCollaboration on gut health innovations using Nagi B-Age assay to explore beta-glucan consumption effects on biological ageing and physiology.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• InVivo Biosystems: InVivo Biosystems (formerly Nemametrix) is the most direct competitor to Nagi Bioscience, offering C. elegans-based contract research services and tools for drug discovery. Both companies target the same customer segments (pharma, biotech, academia) with C. elegans as the core model organism, though InVivo has a longer operating history and broader academic focus.
• NemaLife: NemaLife is a direct competitor offering C. elegans-based drug discovery and phenotypic screening services. Both companies focus on automating C. elegans assays for aging, toxicity, and therapeutic research, targeting similar pharma, biotech, and academic customers with platform plus services offerings.
• Biobide: Biobide offers contract research services using zebrafish as an alternative in vivo model, directly analogous to Nagi's C. elegans platform. Both companies serve pharma, chemical, and cosmetic industries with NAMs-compliant alternative testing services and have similar scientific positioning around ethical, automated in vivo testing.
• ZeClinics: ZeClinics is a zebrafish-focused CRO offering drug discovery and toxicity testing services. As a peer in the alternative in vivo model CRO space, ZeClinics competes with Nagi for pharma and chemical industry customers seeking NAMs-compliant testing, though using zebrafish rather than C. elegans as the model organism.

Broad incumbents

• Charles River Laboratories: Charles River Laboratories is one of the largest preclinical CROs globally, offering end-to-end drug discovery and development services. While they primarily focus on mammalian models, they are expanding NAMs capabilities that could compete with Nagi in toxicology and aging research, particularly given Bayer CropScience's existing CRO relationships.
• Labcorp Drug Development: Labcorp is a global life sciences company offering comprehensive drug development and CRO services. Their scale, broad service portfolio, and enterprise customer relationships make them a competitor for large pharma preclinical contracts that Nagi targets, particularly as they add NAMs and alternative testing capabilities to their portfolio.
• Eurofins Discovery: Eurofins Discovery is a major CRO offering drug discovery services including in vitro and in vivo testing. With broad scientific capabilities and global footprint, they compete for preclinical testing contracts and have been expanding alternative testing methods that could overlap with Nagi's NAMs positioning in toxicology and efficacy studies.

Emerging players

• Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company focused on aging and age-related diseases. While they develop their own therapeutics rather than offer CRO services, they represent both a potential Nagi customer for in vivo validation work and a thematic competitor in the AI-bio convergence and longevity research space.
• Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company using high-throughput phenotypic screening and automation. Their focus on automating biological experiments aligns thematically with Nagi's automation philosophy, and they represent both a potential customer for C. elegans validation work and a thematic competitor in the AI-bio convergence space.
• BioAge Labs: BioAge Labs is a clinical-stage biotechnology company discovering drugs that target the biology of aging. As a potential Nagi customer for preclinical aging validation, they represent the emerging longevity therapeutics market that drives demand for Nagi's services, while also competing for the same scientific talent and longevity-focused capital.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Nagibioscience
• LinkedInlinkedin.com/company/nagibioscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nagi Bioscience